

Hunter Street Medical Centre

20th February 2012

PBS Post Market

Department of Health and Ageing

MDP 900

GPO Box 9848

CANBERRA ACT 2601


I am a family Doctor who has been supervising the use of Pradaxa supplied by Boehringer Ingelheim for twelve patients for more than six months.

Clinical efficacy is not in doubt. There have been no embolic incidents. Cessation of Pradaxa occurred in two patients, one where there was recurrent epistaxis and extensive dermal discolouration and the other with renal impairment deterioration. One other patient continued Pradaxa when the addition of a proton pump inhibitor eliminated epigastric discomfort.

The elimination of the need for repeated, often unstable, INRs has improved patient management.

I add my vote to having Pradaxa subsidised by the P.B.S. without delay.

Yours faithfully,



DR. FRANK SUMMERS

M.A., M.B., B.Chir (Cambridge), M.R.C.S., L.R.C.P. (London), F.R.A.C.G.P.